You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Neurosessments: Developing a quick, objective motor test to prompt cognitivetesting in primary care

    SBC: NEUROSESSMENTS LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is the leading cause of dementia in the United States, affecting one out of every nine older adults. However, Alzheimer’s disease and related dementias (AD/ADRD) can be difficult to diagnose, with physicians missing nearly half of all probable dementia cases. Rates of missed diagnosis are even higher among Black older adults. The majority of ph ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Home Monitoring of Metabolic Disorders

    SBC: SEQUITUR HEALTH CORP            Topic: NICHD

    PROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. GMP Manufacturing and IND Enabling Studies of Extended-Release PNA5: ANovel Therapeutic for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular

    SBC: Proneurogen, Inc            Topic: NIA

    Vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer’s disease related dementias (ADRD) significantly contribute to the 47 million people world-wide who suffer with dementia. This number is estimated to increase to over 130 million people by 2050. Several studies have shown that VCID and conversion to ADRD are strongly correlated with vascular disease, inflammation an ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation

    SBC: IMMUNOPHOTONICS INC            Topic: 102

    Abstract: Immunophotonics is a biotech company developing a synthetic biopolymer, IP-001, to potentiate a systemic immunotherapy via microwave (MWA) thermal tumor ablation for treatment of Hepatocellular carcinoma (HCC). The goal of this SBIR Fast Track is to complete preclinical safety and efficacy testing to support an investigational new drug (IND) application based on the feedback from a meeti ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals

    SBC: BIOMORPH TECHNOLOGIES LLC            Topic: NIAID

    PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is a serious multi-factorial chronic autoimmune disease with an annual 3% increase in the incidence rate that constitutes a major public health challenge and financial burden. T1D involves genetic predisposition, immune system response, and environmental factors that lead to disease initiation and progression. Due to the lack of curative therapies for ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting LRRC8 signaling to prevent and treat arterial thrombosis in type 2 diabetes

    SBC: Senseion Therapeutics, Inc.            Topic: NHLBI

    Project SummaryCardiovascular disease (CVD) including stroke and myocardial infarction (MI), and Type 2 diabetes (T2D) areoverlapping global pandemics. CVD is the most common cause of death in patients with T2D and the economicburden of stroke and myocardial ischemia in patients with T2D is staggering. While newer glycemic controlagents like SGLT2 inhibitors and GLP1 agonists can help reduce CVD e ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government